Home › Neuroendocrine Tumors › Kentucky › Lexington
Neuroendocrine Tumors clinical trials in Lexington, KY
6 studies for Neuroendocrine Tumors are looking for participants at sites in and around Lexington (within about 30 miles). Open a study to see who can join and how to contact the study team.
Recruiting for a study here? Feature it at the top of this page — $99 for 30 days →
Zanzalintinib Versus Everolimus in Participants With Locally Advanced or Metastatic Neuroendocrine Tumors
RecruitingPhase 2/3
- University of Kentucky Markey Cancer Center, Lexington
Carcinoid Syndrome Efficacy Study Featuring an Oral Daily Paltusotine Regimen
RecruitingPhase 3
- University of Kentucky Medical Center, Lexington
Study of RYZ401 in Subjects With Solid Tumors Expressing SSTRs.
RecruitingPhase 1
- Research Facility, Lexington
Project: Every Child for Younger Patients With Cancer
RecruitingObservational study
- University of Kentucky/Markey Cancer Center, Lexington
A Study to Investigate Safety and Effectiveness of CRN09682 in Participants With SST2-Expressing NENs and Other Solid Tumors
RecruitingPhase 1/2
- Crinetics Study Site, Lexington
Targeted Alpha-Particle Therapy for Advanced Somatostatin Receptor Type 2 (SSTR2) Positive Tumors
RecruitingPhase 1/2
- University of Kentucky, Lexington
Neuroendocrine Tumors trials in other cities
- Philadelphia, PA11 studies
- Washington, DC11 studies
- Rochester, MN9 studies
- Houston, TX8 studies
- Chicago, IL7 studies
- St. Louis, MO7 studies
- Columbus, OH7 studies
- Detroit, MI7 studies
- Cleveland, OH7 studies
- Salt Lake City, UT7 studies
- Dallas, TX6 studies
- Miami, FL6 studies
Other studies in Lexington
- Non-Small Cell Lung Cancer23 studies
- Lung Cancer18 studies
- Ovarian Cancer16 studies
- Prostate Cancer14 studies
- Cancer (all types)14 studies
- Breast Cancer14 studies
- Metastatic Cancer11 studies
- Colorectal Cancer11 studies
- Heart Failure11 studies
- Melanoma10 studies
- Acute Myeloid Leukemia10 studies
- Obesity10 studies
From ClinicalTrials.gov, data retrieved Oct 6, 2026. Each study sets its own eligibility; the study team decides who can join.